Anixa is focused on the treatment and prevention of cancer.

Anixa Biosciences, Inc. is a clinical stage biotechnology company focused on the treatment and prevention of cancer.


Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Vaccines

Breast Cancer Vaccine

We are developing a revolutionary vaccine technology focused on treating and preventing multiple forms of breast cancer.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine against ovarian cancer.

Lung, Colon, & Prostate Cancer Vaccines

We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

Read More...

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Read More...

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change